Skip to content
Clinical Trials – home

Ospedale "Morgagni - Pierantoni" di Forlì

Verified siteinfo

Italy Via Carlo Forlanini 34, 47121 Forli', Italy

  • 3 trials recruiting
  • Idiopathic pulmonary fibrosis · Sarcoidosis · IgA nephropathy
  • Adults and children

About Specializations

Ospedale "Morgagni - Pierantoni" di Forlì in Forli', Italy specialises in clinical trials of conditions such as Idiopathic pulmonary fibrosis, Sarcoidosis, IgA nephropathy, Interstitial lung disease, and other specialisations. This site conducts important research.

Main research areas of the site

Nephrology and Kidney Disease Research

At Ospedale "Morgagni - Pierantoni" di Forlì, clinical research in nephrology focuses on immune system diseases and kidney-related conditions, especially IgA nephropathy. The trials are designed to refine treatment choices, compare supportive care strategies, and improve control of kidney damage and proteinuria.

  • IgA nephropathy studies evaluating targeted treatment approaches after kidney biopsy findings
  • Research comparing early corticosteroid use with standard care to better reduce proteinuria
  • Trials assessing whether adding newer kidney-protective therapies can improve outcomes while limiting side effects

This area reflects a strong interest in finding more personalized and safer treatment strategies for chronic kidney disease.

Respiratory and Interstitial Lung Disease Studies

A major part of the site’s research portfolio involves respiratory tract diseases, with a focus on idiopathic pulmonary fibrosis, progressive pulmonary fibrosis, and systemic sclerosis-associated interstitial lung disease. These studies aim to test new therapies, preserve lung function, and slow disease progression in patients with fibrotic lung conditions.

  • Studies in idiopathic pulmonary fibrosis and progressive pulmonary fibrosis exploring treatments that may improve breathing capacity
  • Research on systemic sclerosis-associated interstitial lung disease assessing symptom control and lung function
  • Long-term evaluations of therapies for fibrotic lung disease to understand safety and ongoing benefit

The site contributes to efforts aimed at improving care for chronic lung scarring and related breathing disorders.

Pulmonary Sarcoidosis and Inflammatory Lung Research

The research program also includes studies in pulmonary sarcoidosis, a condition involving inflammation that can affect the lungs and other organs. These trials are focused on testing new medicines, reducing dependence on corticosteroids, and improving disease control.

  • Trials of new anti-inflammatory therapies for pulmonary sarcoidosis with or without extrapulmonary involvement
  • Research aimed at lowering corticosteroid use while maintaining clinical benefit
  • Studies assessing lung function and overall symptom improvement in inflammatory lung disease

This work highlights an emphasis on more targeted treatment options for patients with complex inflammatory respiratory disease.

Cardiovascular Disease and Heart Rhythm Trials

In the field of cardiovascular diseases, the site is involved in research on atrial fibrillation, acute coronary syndrome, chronic coronary syndrome, and transthyretin amyloid cardiomyopathy. The trials are intended to improve treatment effectiveness, reduce complications, and support better long-term heart care.

  • Studies in atrial fibrillation examining safer ways to balance bleeding and ischemic risk after coronary procedures
  • Research in acute coronary syndrome and chronic coronary syndrome focused on optimizing cardiovascular protection
  • Trials for ATTR-CM evaluating whether new therapies can improve cardiac outcomes and disease control

These studies support ongoing efforts to improve care for both common and rare heart conditions.

Infectious Disease and Urinary Tract Infection Research

The site also contributes to bacterial infections research, particularly studies on urinary tract infections. These trials aim to improve antibiotic use, reduce recurrence, and support more effective treatment of febrile infections.

  • Research on febrile urinary tract infections assessing whether shorter antibiotic approaches can remain effective
  • Studies looking at infection recurrence and treatment response after fever resolves
  • Work focused on making antibiotic treatment more precise and patient-friendly

This area shows interest in practical infection management strategies that may help reduce unnecessary antibiotic exposure.

Broader Immune and Fibrotic Disease Innovation

Across its clinical trial portfolio, Nefrologia at this health care site is engaged in research that links immune system diseases, chronic inflammation, and fibrotic disease. The overall goal is to test new therapies and better understand how to slow progression in complex long-term illnesses.

  • Studies exploring new treatment options for inflammatory and fibrotic disorders
  • Trials evaluating whether emerging therapies can improve function and quality of life
  • Research spanning kidney, lung, and heart conditions with shared chronic disease features

The research profile reflects a broad interest in conditions where inflammation, scarring, and long-term organ damage play a central role.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Via Carlo Forlanini 3447121 Forli'Italy
Recruiting now
3 trials
Conditions studied
8
Partner status
Verified site

More sites in Forli'Italy

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

10 clinical trials

A Phase 3 Study of Sapablursen Compared with Placebo in Adults with Polycythemia Vera

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Sapablursen
  • Sponsor:Deciphera Pharmaceuticals Inc.

Sarcoidosis

Recruiting

Study of XTMAB-16 and Prednisolone Sodium Phosphate for Patients with Pulmonary Sarcoidosis

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:XTMAB-16
  • Sponsor:Xentria Inc.

Study on Long-Term Safety of Inhaled Treprostinil for Patients with Fibrotic Lung Disease

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Treprostinil
  • Sponsor:United Therapeutics Corp.

Pulmonary fibrosis

Not yet recruiting

A study to evaluate the effectiveness and safety of admilparant in patients with progressive pulmonary fibrosis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Admilparant
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

A study to evaluate the effectiveness and safety of admilparant in patients with idiopathic pulmonary fibrosis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Admilparant
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Amoxicillin
  • Sponsor:Istituto Di Ricovero E Cura A Carattere Scientifico Materno Infantile Burlo Garofolo

Sarcoidosis

Not yet recruiting

Study on the Effects of XTMAB-16 and Prednisolone in Patients with Pulmonary Sarcoidosis with or without Other Body Involvement

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Prednisolone
  • Sponsor:Xentria Inc.

IgA nephropathy

Not yet recruiting

Study on Corticosteroids, Dapagliflozin, and Drug Combination for Proteinuria in IgA Nephropathy Patients with Active or Chronic Kidney Lesions

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Fondazione Schena Centro Europeo Della Ricerca Sulle Malattie Renali

Study on Vixarelimab for Patients with Idiopathic Pulmonary Fibrosis and Systemic Sclerosis-Associated Interstitial Lung Disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Vixarelimab
  • Sponsor:Genentech Inc.

Pulmonary sarcoidosis

Not recruiting

Study on Efzofitimod for Treating Pulmonary Sarcoidosis in Patients

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Efzofitimod
  • Sponsor:aTYR Pharma Inc.
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.